Assembly Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $230.00K.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $149.00K.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $88.00K, a 8700.00% increase year-over-year.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $37.00K.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $125.00K, a 2400.00% increase from fiscal 2024.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $5.00K.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $1.47M, a 65.38% decline from fiscal 2019.
- Assembly Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $4.24M, a 7.02% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $230.00K 10-Q · filed 2026-08-13 | $504.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $149.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $125.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $37.00K 10-Q · filed 2025-11-10 | |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $5.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $4.00K 10-Q · filed 2025-08-06 | |
| 2020-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $1.47M 10-K · filed 2022-03-11 |
| 2020-09-30 | $843.00K 10-Q · filed 2021-11-04 | $3.97M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $483.00K 10-Q · filed 2021-08-05 | $4.51M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $119.00K 10-Q · filed 2021-05-06 | $4.22M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.24M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.39M 10-Q · filed 2020-11-05 | $1.91M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $191.00K 10-Q · filed 2020-08-05 | $947.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $140.00K 10-Q · filed 2020-05-08 | $2.61M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.96M 10-K · filed 2021-02-25 |
| 2018-09-30 | $419.00K 10-Q · filed 2019-11-07 | $5.15M derived: sum of 4 quarters · filed 2020-03-04 |
| 2018-06-30 | $1.85M 10-Q · filed 2019-08-05 | $4.99M derived: sum of 4 quarters · filed 2020-03-04 |
| 2018-03-31 | $1.49M 10-Q · filed 2019-05-09 | $3.25M derived: sum of 4 quarters · filed 2020-03-04 |
| 2017-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | $2.39M 10-K · filed 2020-03-04 |
| 2017-09-30 | $262.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | |
| 2017-06-30 | $108.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | |
| 2017-03-31 | $640.02K 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $153.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $554.27K 10-K · filed 2018-03-08 |
| 2015-09-30 | $257.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2015-06-30 | $129.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | |
| 2015-03-31 | $167.04K 10-Q · filed 2015-05-08 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $427.82K 10-K · filed 2013-03-18 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | |
| 2012-06-30 | $189.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | |
| 2012-03-31 | $238.62K 10-Q · filed 2012-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |